Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Fifty-seven convalescent patients 14 days after mild-to-moderate COVID-19 infection managed in an outpatient setting were randomized to receive GDS (n = 29) or placebo (n = 28) for 4 consecutive months.

The researchers measured at baseline and at 4 months: (a) perfused boundary region (PBR) of the sublingual microvessels with a diameter range of 4-25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Coronary Circulation, COVID-19, Dietary Supplements, Echocardiography, Doppler, Endothelium, Vascular, Glycocalyx and Glycosaminoglycans.

The authors tagged it with the keywords arterial stiffness, coronavirus disease 2019, endothelial glycocalyx, fucoidan, glycocalyx dietary supplement and pulse wave velocity.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Copper (Supplement).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (European journal of clinical investigation), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.